NORML Submits Public Comments To FDA Regarding The International Scheduling Of Marijuana

The US Food and Drug Administration sought public comments specific to whether changes ought to be recommended regarding imposing international manufacturing and distributing restrictions, under international treaties, on certain drug substances.

Per the FDA: FDA, on behalf of the Secretary of HHS, invites interested persons to submit comments on the notifications from the United Nations concerning these drug substances. FDA, in cooperation with the National Institute on Drug Abuse, will consider the comments on behalf of HHS in evaluating the WHO scheduling recommendations. 

Below is submission filed by Paul Armentano, Deputy Director of NORML.